Shawn Li, principal scientist at Merck & Co., known as MSD outside the Unites States and Canada, talked about the importance ...

The merger will create a specialty company, REGiMMUNE/Kiji TX, for regulatory T cells.

As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...

The Cambridge-GSK Translational Immunology Collaboration builds on an existing scientific relationship between the biopharma company and the university, with the aim of improving outcomes for patients ...